We are international
Donate
• videos TEXT SIZE   
webcasts from medical meetings    back

Dr. Kumar - Phase II Trial of Lenalidomide, Cyclophosphamide, and Dexamethasone (CRd) for Newly Diagnosed Myeloma
Shaji Kumar, MD
Mayo Clinic
Rochester, MN
12.17.07

"At this time we believe the results represent an effective regimen, and future trials need to compare this regimen with other active regimens in the setting of newly-diagnosed multiple myeloma."
Dr. Shaji Kumar


To view the video full screen, click on the small button next to the volume control in the lower right hand corner.

[190] Phase II Trial of Lenalidomide, Cyclophosphamide, and Dexamethasone (CRd) for Newly Diagnosed Myeloma. Session Type: Oral Session

Shaji Kumar, Suzanne R. Hayman, Francis K. Buadi, Martha Q. Lacy, Keith Stewart, Philip R. Greipp, Stephen Russell, Steven Zeldenrust, Morie A. Gertz, Leif Bergsagel, Rafael Fonseca, Jacob Allred, Megan Campbell, John A. Lust, Thomas E. Witzig, Robert A. Kyle, S. Vincent Rajkumar, Angela Dispenzieri Hematology, Mayo Clinic, Rochester, MN, USA; Hematology, Mayo Clinic, Scottsdale, AZ, USA

Background: The combination of lenalidomide and dexamethasone (Rev/Dex) has been shown to be a highly effective therapy for multiple myeloma (MM). Over half of the patients with newly diagnosed MM achieve a complete response with prolonged therapy. More recently, a phase III trial demonstrated improved survival with use of lenalidomide and low dose dexamethasone with one year survival in excess of 90%. We report the initial results from a phase II trial combining lenalidomide and low dose dexamethasone with cyclophosphamide (CRd) as initial therapy of newly diagnosed MM. Methods: The trial was initiated in July 2006 and completed the target accrual of 33 patients by July 2007. The treatment protocol consisted of lenalidomide given orally at a dose of 25 mg daily on days 121 of a 28-day cycle. Dexamethasone (dex) was given orally at a dose of 40 mg on days 1, 8, 15, and 22 of each cycle. Cyclophosphamide at a dose of 300 mg/m2 was given on days 1, 8, and 15 of each cycle. Patients also received an aspirin once daily as thromboprophylaxis. Response was defined as a decrease in serum monoclonal (M) protein by 50% or higher and a decrease in urine M protein by at least 90% or to a level less than 200 mg/24 hours, confirmed at least 4 weeks apart. Results: The median age was 63 years (range, 4479). Eight patients (24%) had ISS stage III disease. At this time, 19 of the 33 patients are evaluable for confirmed responses (i.e., off-study or completed at least 4 cycles of therapy). Of these, 2 achieved VGPR and 13 had a partial response giving an overall response rate of 79%. The response rate was affected by 5 of 19 patients who went off study within three cycles due to toxicities [interstitial nephritis (1 pt), multiple grade 3 toxicities including infection (1 pt) atrial fibrillation and infection (1 pt)] or alternative treatment [no response and possible renal toxicity (1 pt) and progression at 4 cycles (1 pt)]. Overall, hematological toxicity was the most common with grade 4 toxicity seen in 6 patients (20%). Non-hematological grade 3 or higher toxicities included fatigue (4 pts), thrombosis (3 pts) and renal failure (2 pts). One patient with thrombosis came off study for other toxicities, and the other two continued on study with anticoagulation. Thirteen patients (43%) had dose reductions of both cyclophosphamide and lenalidomide, most commonly due to hematological toxicity. So far, 12 patients have gone off study, 6 went to stem cell transplant, 3 due to adverse events, 1 due to disease progression and 2 patients went to alternate treatment. Conclusions: CRd has excellent activity in newly diagnosed myeloma with an estimated overall response rate of 79%. Response evaluation of the entire 33 patients will be presented at the meeting. We believe that the initial use of a 300 mg/m2 dose of cyclophosphamide resulted in 5 of the first 19 pts experiencing early toxicity and withdrawal. As a result, an expansion of the current trial is evaluating lower doses of cyclophosphamide (300 mg fixed dose). Full analysis of this study will be needed to determine if CRd can improve outcome compared to Rd.

Abstract #190 appears in Blood, Volume 110, issue 11, November 16, 2007

Keywords: Induction|Immunomodulatory Thalidomide Analog|Chemotherapy

Disclosure: Research Funding: The clinical trial was funded by Celgene corporation. Off Label Use: Lenalidomide is not approved for treatment of newly diagnosed myeloma.

Monday, December 10, 2007 8:15 AM

Session Info: Simultaneous Session: Myeloma: Frontline Therapy in Newly Diagnosed Multiple Myeloma (7:30 a.m.-9:00 a.m.)


 related articles
Elijah Alexander: AS...
ASH 2007 INTERNATION...
Dr. San Miguel - A P...
Dr. Rajkumar - A Ran...
Dr. Richardson - Len...
Dr. Kumar - Phase II...
Dr. Palumbo - Bortez...
Dr. Palumbo - A Pro...
Dr. Jagannath - A Ph...
Dr. Reeder - Phase I...
Dr. Ludwig - Thalido...
Dr. Zonder - Superio...
Dr. Waage - Melphala...
Dr. San Miguel - Dex...
Dr. Jagannath - Upda...
Dr. Bladé - The Prol...
Dr. Davies - The Com...
Dr. Orlowski: Early ...
Dr. Jakubowiak - A M...
Dr. Richardson - Tan...
Dr. Orlowski - Safet...
Dr. Ocio - Antimyelo...
Dr. Richardson - An ...
Dr. Richardson - Fin...
Dr. Ocio - Triple Co...
Dr. Dispenzieri - Pr...
Dr. Davies - Aminope...
Dr. Zonder - Phase I...
Dr. Aggarwal: Curcum...
Dr. Harousseau - VEL...
Dr. Bruno - An Updat...
Dr. Hajek - Consolid...
Dr. Tosi - Superiori...
Dr. Beksac - Amplitu...
Dr. Ladetto - Consol...
Dr. Tosi - Bortezomi...
Dr. De la Rubia - To...
Dr. Bladé - Tandem A...
Dr. Einsele - An Ove...
Dr. Liebisch - Progn...
Dr. Avet-Loiseau - H...
Dr. Sezer - The Bone...
Dr. Durie - Genetic ...
Dr. Kyle - Monoclona...
Dr. Kumar - Improvin...
Dr. Jakubowiak - Tar...
Dr. Kyle - Prognosti...
Dr. Goldschmidt - An...

Elijah Alexander: ASH 2007: A Patient's Perspective
ASH 2007 INTERNATIONAL WEBCASTS
Dr. San Miguel - A Phase 3 Study Comparing BortezomibMelphalanPrednisone (VMP) with MelphalanPrednisone (MP) in Newly Diagnosed Multiple Myeloma.
Dr. Rajkumar - A Randomized Trial of Lenalidomide Plus High-Dose Dexamethasone (RD) Versus Lenalidomide Plus Low-Dose Dexamethasone (Rd) in Newly Diagnosed Multiple Myeloma (E4A03): A Trial Coordinated by the Eastern Cooperative Oncology Group
Dr. Richardson - Lenalidomide, Bortezomib, and Dexamethasone (Rev/Vel/Dex) as Front-Line Therapy for Patients with Multiple Myeloma (MM): Preliminary Resultsof a Phase 1/2 Study.
Dr. Kumar - Phase II Trial of Lenalidomide, Cyclophosphamide, and Dexamethasone (CRd) for Newly Diagnosed Myeloma
Dr. Palumbo - Bortezomib, Pegylated-Lyposomal-Doxorubicin and Dexamethasone Followed by Melphalan 100 mg/m in Elderly Newly Diagnosed Patients: An Interim Analysis
Dr. Palumbo - A Prospective, Randomized, Phase III Study of Enoxaparin Versus Aspirin Versus Low-Fixed-Dose of Warfarin in Newly Diagnosed Myeloma Patients Treated with Thalidomide-Containing Regimens
Dr. Jagannath - A Phase II Study of Bortezomib (Velcade®), Cylophosphamide (Cytoxan®), Thalidomide (Thalomid®) and Dexamethasone as First-Line Therapy for Multiple Myeloma
Dr. Reeder - Phase II Trial of Myeloma Induction Therapy with Cyclophosphamide, Bortezomib, and Dexamethasone (Cybor-D): Improved Response over Historical Lenalidomide-Dexamethasone Controls
Dr. Ludwig - Thalidomide-Dexamethasone vs. Melphalan-Prednisone as First Line Treatment in Elderly Patients with Multiple Myeloma
Dr. Zonder - Superiority of Lenalidomide (Len) Plus High-Dose Dexamethasone (HD) Compared to HD Alone as Treatment of Newly-Diagnosed Multiple Myeloma (NDMM): Results of the Randomized, Double-Blinded, Placebo-Controlled SWOG Trial S0232
Dr. Waage - Melphalan-Prednisone-Thalidomide to Newly Diagnosed Patients with Multiple Myeloma: A Placebo Controlled Randomised Phase 3 Trial
Dr. San Miguel - Dexamethasone Dose Adjustments Seem To Result in Better Efficacy and Improved Tolerability in Patients with Relapsed/Refractory Multiple Myeloma Who Are Treated with Lenalidomide/Dexamethasone (MM009/010 Sub-Analysis)
Dr. Jagannath - Updated Survival Analyses after Prolonged Follow-Up of the Phase 2, Multicenter CREST Study of Bortezomib in Relapsed or Refractory Multiple Myeloma
Dr. Bladé - The Prolonged Time to Progression with Pegylated Liposomal Doxorubicin + Bortezomib Versus Bortezomib Alone in Relapsed or Refractory Multiple Myeloma Is Unaffected by Extent of Prior Therapy or Previous Anthracycline Exposure
Dr. Davies - The Combination of Velcade, Idarubicin and Melphalan (VIM) Demonstrates Significant Clinical Activity in Relapsed/Refractory Myeloma Patients
Dr. Orlowski: Early Normalization of Serum Free Light Chain Is Associated with Prolonged Time to Progression Following Bortezomib Pegylated Liposomal Doxorubicin Treatment of Relapsed/Refractory Multiple Myeloma
Dr. Jakubowiak - A Multiple Myeloma Research Consortium (MMRC) Multicenter Phase I Trial of Perifosine (KRX-0401) in Combination with Lenalidomide and Dexamethasone in Patients with Relapsed/Refractory Multiple Myeloma (MM): Updated Results
Dr. Richardson - Tanespimycin (T) + Bortezomib (BZ) in Multiple Myeloma (MM): Confirmation of the Recommended Dose Using a Novel Formulation
Dr. Orlowski - Safety and Antitumor Efficacy of the Proteasome Inhibitor Carfilzomib (PR-171) Dosed for Five Consecutive Days in Hematologic Malignancies: Phase 1 Results
Dr. Ocio - Antimyeloma Efficacy of Plitidepsin (Aplidin): From Bench to the Bedside
Dr. Richardson - An Overview of Studies of the New Agent Perifosine (KRX-0401) Alone and in Combination for Patients with Relapsed/Refractory Multiple Myeloma
Dr. Richardson - Final Results of a Phase I Trial of Oral Vorinostat (Suberoylanilide Hydroxamic Acid, SAHA) in Patients with Advanced Multiple Myeloma
Dr. Ocio - Triple Combinations of the HDAC Inhibitor Panobinostat (LBH589) + Dexamethasone with Either Lenalidomide or Bortezomib Are Highly Effective in a Multiple Myeloma Mouse Model
Dr. Dispenzieri - Pre-Clinical Data and Preliminary Patient Results of Intravenous MV-NIS To Treat Relapsed, Refractory Multiple Myeloma
Dr. Davies - Aminopeptidase Inhibition as a Targeted Treatment Strategy in Myeloma
Dr. Zonder - Phase I Trial of HuLuc63 in Multiple Myeloma
Dr. Aggarwal: Curcumin downregulates NF-kB and related genes in patients with multiple myeloma: Results of a phase 1/2 study
Dr. Harousseau - VELCADE/Dexamethasone (Vel/D) Versus VAD as Induction Treatment Prior to Autologous Stem Cell Transplantion (ASCT) in Newly Diagnosed Multiple Myeloma (MM): Updated Results of the IFM 2005/01 Trial
Dr. Bruno - An Update of a Comparison of Nonmyeloablative Allografting with Autografting for Newly Diagnosed Myeloma
Dr. Hajek - Consolidation Therapy Based on Conventional Chemotherapy and Corticoids Do Not Provide Therapeutic Advantage for Newly Diagnosed Patients after Autologous Transplantation
Dr. Tosi - Superiority of Double over Single Autologous Stem-Cell Transplantation for Newly Diagnosed Multiple Myeloma and Prognostic Impact of Complete Response: Final Analysis of Bologna 96 Study
Dr. Beksac - Amplitude of Response, Early Mobilization (M) and Pre-Autologous Transplant (ASCT) Use of Bortezomib (V) and/or Thalidomide(T) Are Predictors of Longer Progression Free (PFS) and/or Overall Survival (OS) in Myeloma
Dr. Ladetto - Consolidation with Bortezomib, Thalidomide and Dexamethasone Induces Molecular Remissions in Autografted Multiple Myeloma Patients
Dr. Tosi - Bortezomib (Velcade)-Thalidomide-Dexamethasone (VTD) vs Thalidomide-Dexamethasone (TD) in Preparation for Autologous Stem-Cell (SC) Transplantation (ASCT) in Newly Diagnosed Multiple Myeloma
Dr. De la Rubia - Toxicity and Early Response after Single Daily Dose of Intravenous Busulfan and Melphalan as Conditioning Regimen for Autologous Stem Cell Transplantation in Patients with Multiple Myeloma. Session Type: Publication Only
Dr. Bladé - Tandem Autologous Transplant Versus Reduced Intensity Conditioned Allogeneic Transplant (Allo-RIC) as Second Intensification in Chemosensitive Patients with Multiple Myeloma (MM) Not Achieving Complete Remission (CR) or Near-CR with a First Autologous Transplant. Results from a Spanish PETHEMA/GEM Study.
Dr. Einsele - An Overview of Two Studies Conducted at the University Clinic of Würzburg
Dr. Liebisch - Prognostic Impact of Chromosomal Abnormalities in Elderly Patients with Multiple Myeloma Treated with High-Dose Melphalan (MEL140) and Autologous Stem Cell Transplantation
Dr. Avet-Loiseau - High-Resolution Genomic Profiles Identify Novel Genes and/or Chromosomal Regions with Prognostic and Oncogenic Significance in Myeloma Patients
Dr. Sezer - The Bone Resorption Marker Serum-ICTP and the Circulating Proteasome Levels Separate ISS-Stages 1-3 and Are the Most Powerful Prognostic Factors for Overall Survival in Newly Diagnosed Symptomatic Multiple Myeloma
Dr. Durie - Genetic Polymorphisms Identify the Likelihood of Bone Disease in Myeloma: Correlations with Myeloma Cell DKK1 Expression and High Risk Gene Signatures.
Dr. Kyle - Monoclonal Gammopathy of Undetermined Significance: Estimated Incidence and Duration Prior to Recognition
Dr. Kumar - Improving Survival in Multiple Myeloma: Impact of Novel Therapies
Dr. Jakubowiak - Targeted Therapy Against Clonogenic Myeloma Cells with Iodine I-131 Tositumomab (Bexxar™).
Dr. Kyle - Prognostic Value of the Serum Free Light Chain Ratio in Patients with Newly Diagnosed Myeloma: Proposed Incorporation into the International Staging System.
Dr. Goldschmidt - Angiogenic Signature of Multiple Myeloma Determined by Gene Expression Profiling


You might also be interested in:

ASH Overview
Elijah Alexander: ASH 2007: A Patient's Perspective
Elijah Alexander
Former NFL lineman and Myeloma Patient shares his reactions on attending ASH for the first time

ASH 2007 INTERNATIONAL WEBCASTS
We are pleased to be able to present overviews of ASH 2007 in French, Spanish, German, Italian, Turkish, and Czech.

Newly Diagnosed Myeloma
Dr. San Miguel - A Phase 3 Study Comparing BortezomibMelphalanPrednisone (VMP) with MelphalanPrednisone (MP) in Newly Diagnosed Multiple Myeloma.
Dr. Jesús San Miguel
Hospital Clinico Universitario
Universidad de Salamanca
Salamanca, Spain
Member, IMF Board of Scientific Advisors

Dr. Rajkumar - A Randomized Trial of Lenalidomide Plus High-Dose Dexamethasone (RD) Versus Lenalidomide Plus Low-Dose Dexamethasone (Rd) in Newly Diagnosed Multiple Myeloma (E4A03): A Trial Coordinated by the Eastern Cooperative Oncology Group
S. Vincent Rajkumar, MD
Mayo Clinic
Rochester, Minnesota
Member, IMF Board of Scientific Advisors

Dr. Richardson - Lenalidomide, Bortezomib, and Dexamethasone (Rev/Vel/Dex) as Front-Line Therapy for Patients with Multiple Myeloma (MM): Preliminary Resultsof a Phase 1/2 Study.
Paul Richardson, MD
Jerome Lipper Myeloma Center
Dana Farber Cancer Institute
Boston, MA
Member, IMF Board of Scientific Advisors

Dr. Kumar - Phase II Trial of Lenalidomide, Cyclophosphamide, and Dexamethasone (CRd) for Newly Diagnosed Myeloma
Shaji Kumar, MD
Mayo Clinic
Rochester, MN

Dr. Palumbo - Bortezomib, Pegylated-Lyposomal-Doxorubicin and Dexamethasone Followed by Melphalan 100 mg/m in Elderly Newly Diagnosed Patients: An Interim Analysis
Antonio Palumbo, MD
Ospedale Molinette
Torino, Italy
Member,IMF Board of Scientific Advisors

Dr. Palumbo - A Prospective, Randomized, Phase III Study of Enoxaparin Versus Aspirin Versus Low-Fixed-Dose of Warfarin in Newly Diagnosed Myeloma Patients Treated with Thalidomide-Containing Regimens
Antonio Palumbo, MD
Ospedale Molinette
Torino, Italy
Member,IMF Board of Scientific Advisors

Dr. Jagannath - A Phase II Study of Bortezomib (Velcade®), Cylophosphamide (Cytoxan®), Thalidomide (Thalomid®) and Dexamethasone as First-Line Therapy for Multiple Myeloma
Sundar Jagannath, MD
St. Vincent's Comprehensive Cancer Center
New York, New York
Member, IMF Board of Scientific Advisors

Dr. Reeder - Phase II Trial of Myeloma Induction Therapy with Cyclophosphamide, Bortezomib, and Dexamethasone (Cybor-D): Improved Response over Historical Lenalidomide-Dexamethasone Controls
Craig B. Reeder, MD
Mayo Clinic
Scottsdale, Arizona

Dr. Ludwig - Thalidomide-Dexamethasone vs. Melphalan-Prednisone as First Line Treatment in Elderly Patients with Multiple Myeloma
Heinz Ludwig, MD
Wilhelminenspital der Stadt Wein
Vienna, Austria
Member, IMF Board of Scientific Advisors

Dr. Zonder - Superiority of Lenalidomide (Len) Plus High-Dose Dexamethasone (HD) Compared to HD Alone as Treatment of Newly-Diagnosed Multiple Myeloma (NDMM): Results of the Randomized, Double-Blinded, Placebo-Controlled SWOG Trial S0232
Jeffrey A. Zonder, MD
Karmanos Cancer Institute
Detroit, Michigan

Dr. Waage - Melphalan-Prednisone-Thalidomide to Newly Diagnosed Patients with Multiple Myeloma: A Placebo Controlled Randomised Phase 3 Trial
Anders Waage, MD
University Hospital
Trondheim, Norway

Relapsed/Refractory Myeloma
Dr. San Miguel - Dexamethasone Dose Adjustments Seem To Result in Better Efficacy and Improved Tolerability in Patients with Relapsed/Refractory Multiple Myeloma Who Are Treated with Lenalidomide/Dexamethasone (MM009/010 Sub-Analysis)
Jesús San Miguel, MD
Hospital Clinico Universitario
Universidad de Salamanca
Salamanca, Spain
Member, IMF Board of Scientific Advisors

Dr. Jagannath - Updated Survival Analyses after Prolonged Follow-Up of the Phase 2, Multicenter CREST Study of Bortezomib in Relapsed or Refractory Multiple Myeloma
Sundar Jagannath, MD
St. Vincent's Comprehensive Cancer Center
New York, NY
Member, IMF Board of Scientific Advisors

Dr. Bladé - The Prolonged Time to Progression with Pegylated Liposomal Doxorubicin + Bortezomib Versus Bortezomib Alone in Relapsed or Refractory Multiple Myeloma Is Unaffected by Extent of Prior Therapy or Previous Anthracycline Exposure
Joan Bladé, MD
Hospital Clinic
Hematology
Barcelona, Spain
Member, IMF Board of Scientific Advisors

Dr. Davies - The Combination of Velcade, Idarubicin and Melphalan (VIM) Demonstrates Significant Clinical Activity in Relapsed/Refractory Myeloma Patients
Faith E. Davies, MD
The Royal Marsden NHS Foundation Trust
Sutton, Surrey, UK
Member, IMF Board of Scientific Advisors

Dr. Orlowski: Early Normalization of Serum Free Light Chain Is Associated with Prolonged Time to Progression Following Bortezomib Pegylated Liposomal Doxorubicin Treatment of Relapsed/Refractory Multiple Myeloma
Robert Z. Orlowski, MD
MD Anderson Cancer Center
Houston, Texas

Dr. Jakubowiak - A Multiple Myeloma Research Consortium (MMRC) Multicenter Phase I Trial of Perifosine (KRX-0401) in Combination with Lenalidomide and Dexamethasone in Patients with Relapsed/Refractory Multiple Myeloma (MM): Updated Results
Andrzej Jakubowiak, MD
University of Michigan Cancer Center
Ann Arbor, MI

New Agents
Dr. Richardson - Tanespimycin (T) + Bortezomib (BZ) in Multiple Myeloma (MM): Confirmation of the Recommended Dose Using a Novel Formulation
Paul Richardson, MD
Jerome Lipper Myeloma Center
Dana Farber Cancer Institute
Boston, MA
Member, IMF Board of Scientific Advisors

Dr. Orlowski - Safety and Antitumor Efficacy of the Proteasome Inhibitor Carfilzomib (PR-171) Dosed for Five Consecutive Days in Hematologic Malignancies: Phase 1 Results
Robert Z. Orlowski, MD
MD Anderson Cancer Center
Houston, Texas

Dr. Ocio - Antimyeloma Efficacy of Plitidepsin (Aplidin): From Bench to the Bedside
Enrique M. Ocio, MD
Hospital Universitario de Salamanca
Salamanca, Spain

Dr. Richardson - An Overview of Studies of the New Agent Perifosine (KRX-0401) Alone and in Combination for Patients with Relapsed/Refractory Multiple Myeloma
Paul Richardson, MD
Jerome Lipper Myeloma Center
Dana Farber Cancer Institute
Boston, MA
Member, IMF Board of Scientific Advisors

Dr. Richardson - Final Results of a Phase I Trial of Oral Vorinostat (Suberoylanilide Hydroxamic Acid, SAHA) in Patients with Advanced Multiple Myeloma
Paul Richardson, MD
Jerome Lipper Myeloma Center
Dana Farber Cancer Institute
Boston, MA
Member, IMF Board of Scientific Advisors

Dr. Ocio - Triple Combinations of the HDAC Inhibitor Panobinostat (LBH589) + Dexamethasone with Either Lenalidomide or Bortezomib Are Highly Effective in a Multiple Myeloma Mouse Model
Enrique M. Ocio, MD
Hospital Universitario de Salamanca
Salamanca, Spain

Dr. Dispenzieri - Pre-Clinical Data and Preliminary Patient Results of Intravenous MV-NIS To Treat Relapsed, Refractory Multiple Myeloma
Angela Dispenzieri, MD
Mayo Clinic
Rochester, Minnesota

Dr. Davies - Aminopeptidase Inhibition as a Targeted Treatment Strategy in Myeloma
Faith E. Davies, MD
The Royal Marsden NHS Foundation Trust
Sutton, Surrey, UK
Member, IMF Board of Scientific Advisors

Dr. Zonder - Phase I Trial of HuLuc63 in Multiple Myeloma
Jeffrey A. Zonder, MD
Karmanos Cancer Institute
Detroit, Michigan

Dr. Aggarwal: Curcumin downregulates NF-kB and related genes in patients with multiple myeloma: Results of a phase 1/2 study
Bahrat Aggarwal, PhD
MD Anderson Cancer Center
Houston, Texas

Transplantation
Dr. Harousseau - VELCADE/Dexamethasone (Vel/D) Versus VAD as Induction Treatment Prior to Autologous Stem Cell Transplantion (ASCT) in Newly Diagnosed Multiple Myeloma (MM): Updated Results of the IFM 2005/01 Trial
Jean Luc Harousseau, MD
Hematologie Clinique
CHU Hotel Dieu
Nantes, France
Member, IMF Board of Scientific Advisors

Dr. Bruno - An Update of a Comparison of Nonmyeloablative Allografting with Autografting for Newly Diagnosed Myeloma
Benedetto Bruno, MD, PhD
San Giovanni Battista Hospital
University of Torino
Torino, Italy

Dr. Hajek - Consolidation Therapy Based on Conventional Chemotherapy and Corticoids Do Not Provide Therapeutic Advantage for Newly Diagnosed Patients after Autologous Transplantation
Roman Hajek, MD
University Hospital Brno
Brno, Czech Republic
Member, IMF Board of Scientific Advisors

Dr. Tosi - Superiority of Double over Single Autologous Stem-Cell Transplantation for Newly Diagnosed Multiple Myeloma and Prognostic Impact of Complete Response: Final Analysis of Bologna 96 Study
Patrizia Tosi, MD
Seràgnoli Institute of Hematology
Bologna, Italy

Dr. Beksac - Amplitude of Response, Early Mobilization (M) and Pre-Autologous Transplant (ASCT) Use of Bortezomib (V) and/or Thalidomide(T) Are Predictors of Longer Progression Free (PFS) and/or Overall Survival (OS) in Myeloma
Meral Beksac, MD
Ankara University
Ibn Sina Hospital
Ankara, Turkey
Member, IMF Board of Scientific Advisors

Dr. Ladetto - Consolidation with Bortezomib, Thalidomide and Dexamethasone Induces Molecular Remissions in Autografted Multiple Myeloma Patients
Marco Ladetto, MD
Divisione Universitaria di Ematologia
L'università di Torino
Torino, Italy

Dr. Tosi - Bortezomib (Velcade)-Thalidomide-Dexamethasone (VTD) vs Thalidomide-Dexamethasone (TD) in Preparation for Autologous Stem-Cell (SC) Transplantation (ASCT) in Newly Diagnosed Multiple Myeloma
Patrizia Tosi, MD
Seràgnoli Institute of Hematology
Bologna, Italy

Dr. De la Rubia - Toxicity and Early Response after Single Daily Dose of Intravenous Busulfan and Melphalan as Conditioning Regimen for Autologous Stem Cell Transplantation in Patients with Multiple Myeloma. Session Type: Publication Only
Javier de la Rubia, MD
University Hospital La Fe
Valencia, Spain

Dr. Bladé - Tandem Autologous Transplant Versus Reduced Intensity Conditioned Allogeneic Transplant (Allo-RIC) as Second Intensification in Chemosensitive Patients with Multiple Myeloma (MM) Not Achieving Complete Remission (CR) or Near-CR with a First Autologous Transplant. Results from a Spanish PETHEMA/GEM Study.
Joan Bladé, MD
Hospital Clinic
Hematology
Barcelona, Spain
Member, IMF Board of Scientific Advisors

Dr. Einsele - An Overview of Two Studies Conducted at the University Clinic of Würzburg
Hermann Einsele, MD
University Clinic of Würzburg
Würzburg, Germany
Member, IMF Board of Scientific Advisors

Dr. Liebisch - Prognostic Impact of Chromosomal Abnormalities in Elderly Patients with Multiple Myeloma Treated with High-Dose Melphalan (MEL140) and Autologous Stem Cell Transplantation
Peter Liebisch, MD
University Hospital of Ulm
Ulm, Germany

New Approaches
Dr. Avet-Loiseau - High-Resolution Genomic Profiles Identify Novel Genes and/or Chromosomal Regions with Prognostic and Oncogenic Significance in Myeloma Patients
Herve Avet-Loiseau, MD
Institut de Biologie
Nantes, France
Member, IMF Board of Scientific Advisors

Dr. Sezer - The Bone Resorption Marker Serum-ICTP and the Circulating Proteasome Levels Separate ISS-Stages 1-3 and Are the Most Powerful Prognostic Factors for Overall Survival in Newly Diagnosed Symptomatic Multiple Myeloma
Orhan Sezer, MD
Medizinische Klinik und Poliklinik II
Berlin, Germany
Member, IMF Board of Scientific Advisors

Dr. Durie - Genetic Polymorphisms Identify the Likelihood of Bone Disease in Myeloma: Correlations with Myeloma Cell DKK1 Expression and High Risk Gene Signatures.
Brian G.M. Durie, MD
Cedars Sinai Comprehensive Cancer Center
Los Angeles, California
Chairman, International Myeloma Foundation

Dr. Kyle - Monoclonal Gammopathy of Undetermined Significance: Estimated Incidence and Duration Prior to Recognition
Robert A. Kyle, MD
Mayo Clinic
Rochester, Minnesota
Chair, IMF Board of Scientific Advisors

Dr. Kumar - Improving Survival in Multiple Myeloma: Impact of Novel Therapies
Shaji Kumar, MD
Mayo Clinic
Rochester, MN

Dr. Jakubowiak - Targeted Therapy Against Clonogenic Myeloma Cells with Iodine I-131 Tositumomab (Bexxar™).
Andrzej Jakubowiak, MD
University of Michigan Cancer Center
Ann Arbor, MI

Dr. Kyle - Prognostic Value of the Serum Free Light Chain Ratio in Patients with Newly Diagnosed Myeloma: Proposed Incorporation into the International Staging System.
Robert A. Kyle, MD
Mayo Clinic
Rochester, Minnesota
Chairman, IMF Board of Scientific Advisors

Dr. Goldschmidt - Angiogenic Signature of Multiple Myeloma Determined by Gene Expression Profiling
Hartmut Goldschmidt, MD
Medizinischen Universitätsklinik und Poliklinik V
University of Heidelberg
Heidelberg, Germany
Member, IMF Board of Scientific Advisors